cGAS-STING, an important pathway in cancer immunotherapy

Table 1 The anti-tumor cGAS-STING agonists

Molecule	Type	Administration method	Development stage	Ref/note
c(di-GMP)	Prokaryotic CDNs	IT	Pre-clinical	[38]
3′,3′-cGAMP	Prokaryotic CDNs	IP	Pre-clinical	[39]
2′,3′-cGAMP	Eukaryotic CDNs	IT	Pre-clinical	[40]
ML-RR-S2-cGAMP	Synthetic CDN agonists	IT	Pre-clinical	[41]
ADU-S100	Synthetic CDN agonists	IT	Phase 1, Phase 2	[41]
ML-RR-S2-CDG	Synthetic CDN agonists	IT	Pre-clinical	[41]
DMXAA	Non-CDN agonists	IT	Phase1, Phase 2, Phase3	[42]
Amidobenzimidazoles	Non-CDN agonists	IV	Pre-clinical	[43]
ExoSTING	Novel STING agonists	IT	Pre-clinical	SITC 2018 P618
MV-626	ENPP1 inhibitor	IP	Pre-clinical	SITC 2018 P410
SB11285	Novel STING agonists	IP, IT, IV	Phase 1	AACR 2017 P-A25
STACT-TREX1	Novel STING agonists	IT, IV	Pre-clinical	SITC 2018 P235
SYN-STING	Novel STING agonists	IT	Pre-clinical	SITC 2018 P624

Abbreviations: IT intratumoral, IV intravenous, IP intraperitoneal, SITC 2018 Society for the Immunotherapy of Cancer 2018 Annual Meeting, AACR 2017 American Association for Cancer Research 2017 Conference on Tumor Immunology and Immunotherapy

ISSN: 1756-8722